skip to main content

Lowenstein Sandler LLP | The contents of this website contain attorney advertising. | Results may vary depending on your particular facts and legal circumstances.

Search
Smart Search Icon
Header Search

Recent Searches

Clear all Searches

Relevant Insights

Featured Content

view all search results
Search Close
Hamburger
profile Icon for Mobile

Michael J. Lerner

Partner
Chair, Life Sciences Group

New Jersey
T: +1 973.597.6394 F: +1 973.597.6395 mlerner@lowenstein.com
  • BIO
  • EXPERIENCE
  • NEWS & INSIGHTS

See more section

Michael Lerner provides strategic judgment and practical advice regarding diverse matters for pharmaceutical, life sciences, and health care companies. Clients–including public and private pharmaceutical, biotechnology, medical device, and other health care companies, as well as their investors and investment banks–value his extensive experience as both in-house counsel and outside legal and business advisor.

This background has contributed to Michael's stellar record of successful outcomes in product acquisitions and divestitures, technology licensing, sales and marketing practices, mergers and acquisitions, intellectual property, corporate compliance, employment law, and regulatory matters. Importantly, he understands the interplay of all these factors and how to manage them effectively for the optimum completion of each transaction.

Prior to joining Lowenstein Sandler, Michael was Senior Vice President and General Counsel of EKR Therapeutics, a specialty pharmaceutical company focusing on acute care hospital products. That position followed six years as Vice President and General Counsel at Reliant Pharmaceuticals Inc., which Michael helped grow into one of the nation's largest privately held pharmaceutical companies before it was acquired by GlaxoSmithKline in 2007. As part of Reliant's senior management team, he was lead inside lawyer on product acquisitions and dispositions totaling in excess of $650 million, and helped the company raise more than $660 million in equity and debt.

Earlier in his career, Michael was partner in charge of the pharmaceutical and life sciences practice at a midsize law firm, representing startup, specialty, and large pharmaceutical and other health care-related companies in corporate, partnering, and licensing matters.

Michael is Chairman of the board of directors of the Blanche and Irwin Lerner Center for the Study of Pharmaceutical Management Issues at Rutgers Business School.

  • Represented Edesa Biotech, Inc. (NASDAQ: EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, in its at-the-market offering of up to $20 million of common shares.
  • Represented Wedgewood Village Pharmacy LLC, a veterinary compounding pharmacy, in its acquisition of Front Range Laboratories, Inc., a full-service testing laboratory specializing in testing compound medications focused on animal health.
  • Representing Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a precision oncology company, in its exclusive [in-]licensing agreement with CSPC Megalith Biopharmaceutical Co., Ltd, a subsidiary of CSPC Pharmaceutical Group Limited (CSPC; HKEX: 01093), for the development and commercialization of CRB-701 (SYS6002), a novel clinical stage antibody drug conjugate (ADC) targeting Nectin-4.
  • Represented Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, in its agreement to acquire all of the assets of Healion Bio, Inc., including its entire portfolio of next-generation antiviral technology assets.
  • Represented Coya Therapeutics, Inc. (Nasdaq: COYA), a clinical-stage biotechnology company, in its $15,250,000 initial public offering of common stocks and warrants.
  • Represented Cingulate Inc. (Nasdaq: CING), a clinical-stage biopharmaceutical company, in an At-the-Market Offering of common stock.
  • Represented ZyVersa Therapeutics, Inc., a clinical-stage specialty biopharmaceutical company, in its agreement with blank-check SPAC Larkspur Health Acquisition Corp. (NASDAQ: LSPR) to enter into a definitive business combination agreement, resulting in an estimated pro forma company valuation of approximately $108.92 million.
  • Represented Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, in connection with its $15 million private placement of convertible redeemable preferred stock.
SEE MORE

Education

  • Hofstra University School of Law (J.D. 1983)

    Boston University (B.A. 1980), Business Administration, cum laude

Admissions

  • New Jersey
  • District of Columbia

Related Areas

Subscribe